Thanks, Arvind. Please turn to Slide 13. Let me start with some further color on our performance by sector. Within Semi-Cap, our second quarter performance was up 5% year-over-year and 4% sequentially, a bit better than our expectations entering the quarter as we continue to gain share. We’re starting to see signs of recovery from existing programs within key customers, while at the same time benefiting from several new wins which are beginning to ramp. This win momentum continued in the second quarter, highlighted by a large new program win at an OEM where we’re becoming a second source to support the projected growth plan. This quarter also saw us continue to build upon our engineering wins, reinforcing that we are not only a trusted supplier in building semiconductor capital equipment, but increasingly as a design partner. We continue to be optimistic about the multiple catalysts driving future growth in the Semi-Cap sector and are pursuing this with continued capital investment as evidenced by the planned opening of our newest building in Penang, Malaysia later this quarter. Nearer term, although some customers are still bringing inventory levels down, we believe we are in the early stages of recovery of the market’s recovery, which we will believe will enable us to grow Semi-Cap revenue in the low-double-digit range this year. Looking to 2025, signs are pointing to the potential for a broadly improved demand environment. Given our program wins over the last several quarters, coupled with our capacity expansion, I’m confident we’re in a great position to capture this opportunity and continue to gain share. In Medical, as we have seen over the last couple of quarters, end demand softness exacerbated by OEM inventory consumption has challenged sector performance notably in medical devices. Our June quarter revenue was down 23% year-over-year. While in the near-term we expect these headwinds will persist, we continue to secure new program wins in manufacturing and engineering in both the medical device and biotech subsectors. Looking forward, we expect these new programs will begin to contribute as we progress through 2025. In the meantime, we expect Medical sector revenue to remain consistent with current levels in the second half of 2024. Turning to Complex Industrials, we continue to extend our share in key growth markets with manufacturing wins in the quarter including test and measurement and automatic ID and data capture solutions. Very importantly, as a sign of future growth in our industrial business, we secured over a dozen engineering wins this past quarter that we expect will lead to manufacturing wins. Industrial’s revenue in Q2 was down 15% year-over-year and flat sequentially. Although our new program win momentum continues, we are seeing near-term demand softness impact several of our existing programs. Like many of our peers, we expect these conditions to persist during the September quarter with early indications of a potential return to growth exiting 2024. Turning to A&D, we had another strong quarter of revenue performance, up 36% year-on-year and 3% sequentially. Our Defense business continues to see demand strength from both existing business and ramping new program wins. Continued improvement in our supply chain is also benefiting us as we are more able to fully meet demand. Within aerospace, demand has stayed strong for several quarters with a good balance between commercial air and space applications. As an example of this, during the quarter, we won a substantial expansion of existing program with a commercial air customer, while at the same time winning multiple new manufacturing wins within the Space subsector. While these are early stage, the breadth of our momentum here is encouraging. Looking at September quarter, we expect revenue growth solidly both on a sequential and year-over-year basis. Given our year-to-date performance and back-half expectations, A&D revenue on a full-year basis is expected to grow in excess of 20%. Total AC&C revenue declined 26% year-over-year and 11% sequentially in the June quarter. We expect sector pressures to persist through the back-half of the year driven by the completion of several high-performance computing programs in the first half and continued pressure in our Communications subsector as a result of significant customer disengagement as discussed last quarter. Despite the near-term revenue challenges, we continue to win significant new business in the quarter. Just to highlight, one, we were awarded manufacturing for a family of wireless transport and access systems, which we expect will contribute to a return to growth in this sector in 2025. In summary, please turn to Slide 14. Once again, I want to thank the Benchmark team for another solid quarter built on consistent execution and delivery. Despite the challenging market dynamics, we continue to invest in our customer success in support of our mutual future growth. Evidence of this is our ability to build on business with both new logos and expanding our share with existing customers, all while driving operating efficiencies to improve margins while bringing costs down for our customers. As I look at the 2025 objectives we provided back in Q4 of 2022, we continue to make steady progress on almost every metric. The one exception is revenue growth, which has been impacted by the macro environment. Despite this demand volatility, we’ve delivered year-on-year non-GAAP gross and operating margin expansion every quarter since introducing our 2025 target model. We’re well on our way to achieving our goal of greater than 5% non-GAAP operating margin on a full-year basis. Also per our 2025 targets, we remain committed to working down inventory and driving free cash flow. Our second quarter inventory was down $157 million year-over-year, helping us to achieve our 5th consecutive quarter of positive free cash flow. Our focus on inventory is not letting up and we expect continued improvement. This provides us confidence to increase our free cash flow forecast for 2024 to greater than $120 million. Lastly, we committed to returning capital to investors. Today, we announced that the Board has approved an increase to our regular quarterly dividend to $0.17 per share effective immediately. Although, we did not repurchase shares in the quarter, we intend to do so in coming periods. Looking a bit further out, we are seeing clear indications supporting growth across many, if not all of our sectors during the course of 2025. A&D remains strong. Semi-Cap is poised for reacceleration and we believe industrials will begin to recover later this year. Medical and AC&C may take a little more time, but we’re cautiously optimistic about the growth for each later next year. Meantime, we will remain disciplined operators and steadfast supporters of our incredible set of customers. Only by doing this can we best position ourselves to maximize the opportunities in front of us as the demand environment improves. With that, I’ll now turn the call over to the operator to conduct our Q&A session.